United Therapeutics (UTHR) Misses Q4 EPS by 21c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $497.33 +1.99%
Revenue Growth %: -1.2%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.51, $0.21 worse than the analyst estimate of $3.72. Revenue for the quarter came in at $415.2 million versus the consensus estimate of $427.62 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- HSBC explains why risk assets continue to ignore every negative catalyst
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
